Crizotinib in Patients With MET-Amplified NSCLC

Area of Science:

• Oncology
• Genetics

Background:

• MET amplification is a rare but actionable driver in non-small cell lung cancer (NSCLC).
• Understanding MET amplification's impact on treatment response is crucial for personalized medicine.

Purpose of the Study:

• To investigate the clinical activity of crizotinib in NSCLC patients with varying levels of MET amplification.
• To assess the correlation between MET amplification levels and treatment outcomes.

Main Methods:

• 38 NSCLC patients with MET-to-CEP7 ratio ≥1.8 received crizotinib.
• Patients were categorized into high, medium, and low MET amplification groups.
• Objective response rate (ORR), duration of response, and progression-free survival were evaluated.

Main Results:

• High-level MET amplification (n=21) showed the highest ORR (38.1%) and longest median progression-free survival (6.7 months).
• Patients with concurrent MET exon 14 alterations showed objective responses.
• No responses were observed in patients with concurrent KRAS, BRAF, or EGFR mutations.

Conclusions:

• High-level MET-amplified NSCLC patients demonstrated the best response to crizotinib.
• Combined diagnostic approaches for MET and other oncogenes could improve patient selection for crizotinib therapy.